Congruence Therapeutics Announces Participation In The 24Th Annual Needham Virtual Healthcare Conference

(MENAFN- PR Newswire)

MONTREAL, March 26, 2025 /PRNewswire/ -- Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA-driven Parkinson's disease and AAT-deficient lung and liver disease, announced today its participation in the 24^th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025.

This event is being held in a virtual format during which Company management will deliver a presentation and participate in one-on-one meetings with investors. Dr. Clarissa Desjardins, Chief Executive Officer of Congruence, will present on Monday, April 7, 2025, at 10:15 am ET.

About Congruence Therapeutics

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, RevenirTM, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson's Disease, and α1-Antitrypsin Deficiency. Congruence is further deploying its discovery platform to support two recently executed multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors for the treatment of solid tumors and metabolic diseases.

For more information, please visit .

Company Contact
Charles Grubsztajn
Chief Operating Officer
[email protected]

Media Contact
Amy Conrad
Juniper Point
[email protected]
858-366-3243

SOURCE Congruence Therapeutics

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN26032025003732001241ID1109361307